UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1943-01-01
- Employees
- 8.1K
- Market Cap
- -
Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation
Recruiting
- Conditions
- Cancer Patients Receiving Stereotactic Body RTX
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 5000
- Registration Number
- NCT02170181
HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer
Not Applicable
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: HylaCareDrug: Placebo
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT02165605
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis
Completed
- Conditions
- Foot UlcerOsteomyelitisDiabetes
- Interventions
- Other: 1 cohort, standard care, observational
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT02165579
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Everolimus for Children With Recurrent or Progressive Ependymoma
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 11
- Registration Number
- NCT02155920
- Locations
- 🇺🇸
UT Southwestern Medical Center / Children's Medical Center, Dallas, Texas, United States
🇺🇸Baylor College of Medicine / Texas Children's Hospital, Houston, Texas, United States
🇺🇸Lucile Packard Children's Hospital Stanford University, Stanford, California, United States
A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block
Completed
- Conditions
- Upper Extremity Surgery
- Interventions
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 97
- Registration Number
- NCT02151487
- Locations
- 🇺🇸
Parkland Health Hospital System, Dallas, Texas, United States
Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate or CAPTURE Study
Completed
- Conditions
- Myelitis, TransverseFlaccid Paraplegia, Incomplete, AcuteFlaccid Paraplegia, Complete, Acute
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 106
- Registration Number
- NCT02144935
- Locations
- 🇺🇸
UTexasSouthwestern, Dallas, Texas, United States
Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer
Phase 2
Active, not recruiting
- Conditions
- Renal Cancers
- Interventions
- Radiation: Stereotactic Ablative Radiation Therapy
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT02141919
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin
Phase 2
Completed
- Conditions
- Hepatocellular Cancer
- Interventions
- Other: Oncozene-DEB-TACE
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT02141906
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Intacs Prescription Inserts for Keratoconus Patients
Not Applicable
Recruiting
- Conditions
- Keratoconus
- Interventions
- Device: Intacs
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT02138669
- Locations
- 🇺🇸
UTSW Medical Center at Dallas, Dallas, Texas, United States
A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT02138292
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath